Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huh Kyungmin | - |
dc.contributor.author | Na Yewon | - |
dc.contributor.author | Kim Young-Eun | - |
dc.contributor.author | Radnaabaatar Munkhzul | - |
dc.contributor.author | Peck Kyong Ran | - |
dc.contributor.author | Jung Jaehun | - |
dc.date.accessioned | 2021-07-24T14:41:00Z | - |
dc.date.available | 2021-07-24T14:41:00Z | - |
dc.date.created | 2021-07-12 | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81749 | - |
dc.description.abstract | We used the nationwide claims database to calculate the incidence of thrombotic events and predict their overall 2-week incidence. From 2006 to 2020, the incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC) tended to increase. Unlike intracranial venous thrombosis (ICVT) and intracranial thrombophlebitis (ICTP), which showed no age difference, other venous embolism, and thrombosis (OVET), DIC, DVT, and PE were significantly more common in over 65 years. The overall 2-week incidence of ICVT was 0.21/1,000,000 (95% confidence interval [CI], 0.11–0.32). ICTP, OVET, DIC, DVT and PE were expected to occur in 0.08 (95% CI, 0.02– 0.14), 7.66 (95% CI, 6.08–9.23), 5.95 (95% CI, 4.88–7.03), 13.28 (95% CI, 11.92–14.64), 14.09 (95% CI, 12.80–15.37) per 1,000,000, respectively. To date, of 8,548,231 patients vaccinated with ChAdOx1 nCoV-19 in Korea, two had confirmed thrombosis with thrombocytopenia syndrome within 2 weeks. The observed incidence of ICVT after vaccination was 0.23/1,000,000. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한의학회 | - |
dc.relation.isPartOf | Journal of Korean Medical Science | - |
dc.title | Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000672677000006 | - |
dc.identifier.doi | 10.3346/jkms.2021.36.e197 | - |
dc.identifier.bibliographicCitation | Journal of Korean Medical Science, v.36, no.27, pp.1 - 6 | - |
dc.identifier.kciid | ART002737758 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85111417144 | - |
dc.citation.endPage | 6 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | Journal of Korean Medical Science | - |
dc.citation.volume | 36 | - |
dc.citation.number | 27 | - |
dc.contributor.affiliatedAuthor | Na Yewon | - |
dc.contributor.affiliatedAuthor | Radnaabaatar Munkhzul | - |
dc.contributor.affiliatedAuthor | Jung Jaehun | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Thrombosis with Thrombocytopenia Syndrome | - |
dc.subject.keywordAuthor | Vaccination | - |
dc.subject.keywordAuthor | Vaccine Adverse Events | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.